Sonelokimab

Tax included
Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research.
MedChemExpress 
HY-P99397

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
COVID-19-immunoregulation
CAS
1414386-05-2